Dr Ulrike Lorch
Group Scientific Lead – Clinical Trial Design and Methodology
Dr Ulrike Lorch is a highly experienced research physician having conducted more than 220 early phase clinical trials as Principal Investigator or Co-investigator. She has special expertise in adaptive study design in early phase clinical trials, First-into-Human and other exploratory studies in healthy volunteers and patients of all ages, ethnic comparison, cardiac safety (including TQT), pain and gastrointestinal pH monitoring studies.
She holds Specialist Accreditation in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK) and a Fellow of the Royal College of Anaesthetists (UK). Dr Lorch is the Director of Human Pharmacology at the Faculty of Pharmaceutical Medicine and Educational Supervisor for physicians participating in Pharmaceutical Medicine Specialty Training.
In her role as Medical Director at Richmond Pharmacology she was instrumental in obtaining Standard and Supplementary Medicines and Healthcare Products Regulatory Agency (MHRA) Phase I Accreditation. As a Principal Investigator she is accredited to conduct all types of Phase I studies, including those that, due to potential risks, require review by the Expert Advisory Group in addition to the standard review by the MHRA.
Dr Lorch is a member of the British Association of Pharmaceutical Physicians (BrAPP), a Committee member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK), the Phase I Advisory Group (National Research Ethics Service, Health Research Authority, UK), the Japanese Society of Pharmacology and Therapeutics and the Arbeitsgemeinschaft fur Angewandte Humanpharmakologie (AGAH, Germany). She is also a member of the AGILE Clinical Trial Platform Steering Committee.
At Richmond Research Institute Dr Lorch leads our clinical trial design and methodology research group. She is currently investigating how computer-based automated learning could be used to develop an algorithm that provides grading for adverse drug reactions based on input factors such as symptoms, laboratory results and patient effects.
- Fellow: Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians
- Fellow: Royal College of Anaesthetists
- Member: Board of Examiners of the Faculty of Pharmaceutical Medicine
- Member: Annual Review of Competence Progression (ARCP) Faculty of Pharmaceutical Medicine
- Member: British Association of Pharmaceutical Physicians
- Member: Association for Human Pharmacology in the Pharmaceutical Industry
- Member: Phase I Advisory Group
- Member: Japanese Society of Pharmacology and Therapeutics
- Member: Arbeitsgemeinschaft fur Angewandte Humanpharmakologie, Germany
- Member, Landesärztekammer Hessen, Frankfurt am Main, Germany
- Member: Trial Steering Group Of the AGILE
- Member: European CRO Federation's (EUCROF) Clinical Trial Legislation Working Group
- Member: Clinical Pharmacology Scientist Apprenticeship Trailblazer, Clinical Pharmacology Skills Alliance, UK